Angiotensin-receptor blockers in heart failure: Evidence from the CHARM trial

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 8, 2004, Pages 665-673

  Bhakta, Shyam ^a   Dunlap, Mark E ^b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; METOPROLOL; NESIRITIDE; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; COUGHING; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 4444240878     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.8.665     Document Type: Article

References (22)

1. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
2. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003; 362:772-776.
3. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
4. Pfeiffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM Overall programme. Lancet 2003; 362:759-766.
5. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345:1689-1697.
6. Foody JM, Parrell MK, Krumholz HM. Beta-blocker therapy in heart failure. JAMA 2002; 287:883-889.
7. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:3-13.
8. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003; 289:712-718.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
12. Publication Committee for the VMAC Investigators. IV nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA 2002; 287:1531-1540.
13. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289:730-740.
14. Sharma JN. Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol 2003; 43:1187-1195.
15. Hunt SA, Baker DW, Chin MW, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001; 38:2101-2113.
16. Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995; 75:967-968.
17. Papademetriou V, Dunlap ME. Management of systolic heart failure. Cardiol Rev 2003; 20(11):12-20.
18. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly, ELITE). Lancet 1997; 349:747-752.
19. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
20. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999; 100:1056-1064.
21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
22. Effect of enalapril on survival in patients with reduced left ventricular ejection and congestive heart failure: the SOLVD investigators. N Engl J Med 1991; 325:293-302.